Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

189.92 -0.83 (-0.44%)
Streaming Delayed Price Updated: 10:50 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data. 
Via Benzinga
3 Profitable Stocks Skating on Thin Ice
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade
The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases. 
Via Stocktwits
Topics Intellectual Property
How Is The Market Feeling About AbbVie?
Via Benzinga
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Topics Government World Trade
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Artificial Intelligence
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs. 
Via Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial
AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial. 
Via Benzinga
AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail Cheer
Atogepant had fewer discontinuations in the study involving 545 participants due to adverse events than Topiramate. 
Via Stocktwits
Topics Economy
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
Via Benzinga
Topics Artificial Intelligence Initial Public Offering
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged. 
Via Benzinga
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood
The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data. 
Via Stocktwits
AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence
The company stated that no safety signals were observed in the study comparing the efficacy and safety of Venetoclax in combination with Azacitidine compared to Azacitidine and placebo in the treatment... 
Via Stocktwits
1 Cash-Producing Stock for Long-Term Investors and 2 to Steer Clear Of
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
AbbVie Stock Rises After FDA Approves Expanded Treatment Scope For Mavyret, But Retail Needs More To Cheer
The approval makes Mavyret the first and only oral eight-week direct-acting antiviral therapy for people with Acute Hepatitis C Virus. 
Via Stocktwits
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data. 
Via Benzinga
Recent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stock
Via Benzinga
1 S&P 500 Stock with Competitive Advantages and 2 to Steer Clear Of
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Economy Stocks
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks
Via The Motley Fool
Topics Economy World Trade
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Cheap Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Topics Economy
4 Forever Dividend Stocks to Buy
These companies provide growing cash flows. 
Via The Motley Fool
Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.